Earnings results for TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD, Inc. is expected* to report earnings on 03/02/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.19.
Analyst Opinion on TherapeuticsMD (NASDAQ:TXMD)
6 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $7.55, predicting that the stock has a possible upside of 396.71%. The high price target for TXMD is $15.00 and the low price target for TXMD is $1.20. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
TherapeuticsMD has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating. According to analysts’ consensus price target of $7.55, TherapeuticsMD has a forecasted upside of 396.7% from its current price of $1.52. TherapeuticsMD has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD does not currently pay a dividend. TherapeuticsMD does not have a long track record of dividend growth.
Insiders buying/selling: TherapeuticsMD (NASDAQ:TXMD)
In the past three months, TherapeuticsMD insiders have not sold or bought any company stock. Only 13.76% of the stock of TherapeuticsMD is held by insiders. 52.56% of the stock of TherapeuticsMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of TherapeuticsMD (NASDAQ:TXMD
Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.58) to ($0.30) per share. The P/E ratio of TherapeuticsMD is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of TherapeuticsMD is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. TherapeuticsMD has a P/B Ratio of 50.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here